Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT01494506
Registration number
NCT01494506
Ethics application status
Date submitted
14/12/2011
Date registered
19/12/2011
Date last updated
17/06/2016
Titles & IDs
Public title
Study of MM-398 With or Without 5-FU/LV, Versus 5-FU/LV in Patients With Metastatic Pancreatic Cancer
Query!
Scientific title
A Randomized, Open Label Phase 3 Study of MM-398, With or Without 5-Fluorouracil and Leucovorin, Versus 5 Fluorouracil and Leucovorin in Patients With Metastatic Pancreatic Cancer Who Have Failed Prior Gemcitabine-based Therapy
Query!
Secondary ID [1]
0
0
MM-398-07-03-01
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
NAPOLI-1
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Metastatic Pancreatic Cancer
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Pancreatic
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - MM-398
Treatment: Drugs - 5 Fluorouracil
Treatment: Drugs - Leucovorin
Experimental: MM-398 - MM-398 120 mg/m2 Q3W IV. Note: The published dose of ONIVYDE was expressed as the irinotecan hydrochloride trihydrate until October 2015. It is now expressed as the irinotecan free base. Converting a dose based on irinotecan hydrochloride trihydrate to a dose based on irinotecan free base is accomplished by substituting the Molecular Weight of irinotecan hydrochloride trihydrate (677.19 g/mole) with the Molecular Weight of irinotecan free base (586.68 g/mole), which results in a conversion factor of 0.866. 120 mg/m2 dose of irinotecan hydrochloride trihydrate is equivalent to 100 mg/ m2 of irinotecan free base.
Active comparator: 5 Fluorouracil and Leucovorin IV - 5 Fluorouracil and Leucovorin IV
Experimental: MM-398, 5-FU and Leucovorin - MM-398 80 mg/m2, 5-FU and Leucovorin Q2W IV. Note: The published dose of ONIVYDE was expressed as the irinotecan hydrochloride trihydrate until October 2015. It is now expressed as the irinotecan free base. Converting a dose based on irinotecan hydrochloride trihydrate to a dose based on irinotecan free base is accomplished by substituting the Molecular Weight of irinotecan hydrochloride trihydrate (677.19 g/mole) with the Molecular Weight of irinotecan free base (586.68 g/mole), which results in a conversion factor of 0.866. 80 mg/m2 dose of irinotecan hydrochloride trihydrate is equivalent to 70 mg/ m2 of irinotecan free base.
Treatment: Drugs: MM-398
Arm A: MM-398 120 mg/m2 IV Q3W
Arm C: MM-398 80mg/m2 IV Q2W
Treatment: Drugs: 5 Fluorouracil
Arm B: 5 Fluorouracil 2000 mg/m2 IV for 4 weeks followed by 2 weeks of rest every 6 weeks
Arm C: 5 Fluorouracil 2400 mg/m2 IV every 2 weeks
Treatment: Drugs: Leucovorin
Arm B: Leucovorin 200 mg/m2 IV for 4 weeks followed by 2 weeks of rest every 6 weeks
Arm C: Leucovorin 400 mg/m2 IV every 2 weeks
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Overall Survival
Query!
Assessment method [1]
0
0
Overall survival was the primary efficacy endpoint of the study and was defined as the time from the date of patient randomization to the date of death or the date the patient was last known to be alive. OS was summarized by Kaplan-Meier methodology for each treatment group. Pairwise treatment group comparisons were carried out using unstratified log rank analyses on the ITT population. Hazard ratio estimates are from Cox regression analysis.
The comparison of Arm C is based only on patients who were randomized under the 3-arm version of the protocol. Consequently, the 5-FU+Leucovorin (Combo Therapy Comparison) group is a subset of all patients randomized to 5-FU+Leucovorin, which is the Mono Therapy Comparison control and contains patients randomized under both the 2-arm and 3-arm versions of the protocol.
Query!
Timepoint [1]
0
0
From randomization to death; until the data cut off 14 Feb 2014. The maximum time in follow up was 25 months.
Query!
Secondary outcome [1]
0
0
Progression Free Survival
Query!
Assessment method [1]
0
0
Progression-free survival was defined as the time from the date of randomization to the date of disease progression, or death (any cause) on or prior to the clinical cutoff date, whichever occurred earlier. Participants who did not have disease progression or had not died were censored at the date of the last tumor assessment. Patients with two or more consecutive missing response assessments prior to a visit with documented progression (or death) were censored at the last date of tumor assessment when the patient was documented to be progression free. PFS was summarized using Kaplan-Meier methods.
The comparison of Arm C is based only on patients who were randomized under the 3-arm version of the protocol. Consequently, the 5-FU+Leucovorin (Combo Therapy Comparison) group is a subset of all patients randomized to 5-FU+Leucovorin, which is the Mono Therapy Comparison control and contains patients randomized under both the 2-arm and 3-arm versions of the protocol.
Query!
Timepoint [1]
0
0
Randomization until disease progression or death from any cause; Until the data cut off of 14 Feb 2014. The maximum time in follow up was 25 months.
Query!
Secondary outcome [2]
0
0
Objective Response Rate
Query!
Assessment method [2]
0
0
The objective response rate was a secondary efficacy endpoint of the study and was defined by the percentage of patients in the study population with a best overall response of Complete Response (CR) or Partial Response (PR) as assessed by the investigator. Best overall response was defined per RECIST (version 1.1) recorded from randomization until progression or end of study. RECIST (v 1.1) criteria does not require confirmation of response, but an additional, more stringent analysis was also conducted, with designation of CR (or PR) requiring confirmation of response at least 4 weeks following the initial assessment of CR (or PR). Stable disease (SD) required an assessment of SD at least 6 weeks after starting treatment. Subjects with insufficient data for response classification were classified as Not Evaluable for best overall response, and as a non-responder for objective response, in the ITT population. Treatment groups are as indicated for the primary outcome of OS.
Query!
Timepoint [2]
0
0
Assessment every 6 weeks after initial response; Day 1 to data cut off of 14 Feb 2014; maximum time on study 25 months.
Query!
Secondary outcome [3]
0
0
Time to Treatment Failure
Query!
Assessment method [3]
0
0
Time from randomization to discontinuation of treatment for any reason, including disease progression, treatment toxicity or death.
Query!
Timepoint [3]
0
0
Randomization to treatment discontinuation (any cause). The maximum time in follow up was 25 months
Query!
Secondary outcome [4]
0
0
Percentage of Patients With Clinical Benefit Response
Query!
Assessment method [4]
0
0
Composite measure based on patient-reported pain (per VAS), patient-reported pain medication, KPS, and weight. Clinical benefit is indicated by either:
(a) improvement in pain (less pain intensity with stable or decreased pain medication; or less pain medication with stable or decreased pain intensity) with stable or improved KPS; or (b) improvement in KPS with stable or improved pain.
With stable for KPS and pain, clinical benefit may be indicated with an observation of positive weight change.
Clinical benefit response (CBR) was classified weekly and a patient was considered a clinical benefit responder if clinical benefit was observed and maintained over a 4 week period.
Query!
Timepoint [4]
0
0
Randomization to treatment discontinuation.The maximum time in follow up was 25 months
Query!
Secondary outcome [5]
0
0
Percentage of Patients With Tumor Marker (CA 19-9) Response
Query!
Assessment method [5]
0
0
Tumor marker response (TMR) was evaluated by the change in CA19-9 serum levels. Response was defined as a decrease of 50% of CA19-9 in relation to the baseline level at least once during the treatment period.
Query!
Timepoint [5]
0
0
Baseline to treatment discontinuation every 6 weeks; The maximum time in follow up was 25 months
Query!
Secondary outcome [6]
0
0
EORTC-QLQ-C30
Query!
Assessment method [6]
0
0
This patient recorded outcome consists of 15 subscales in 3 independent domains: global health-related quality of life (HRQoL), functional scales (cognitive, emotional, physical, role and social functioning), and symptom scales (appetite loss, constipation, diarrhea, dyspnea, fatigue, insomnia, nausea and vomiting, and pain). For each subscale, patients were classified as improved, worsened or stable. Improvement is indicated by achievement of subscale score at least 10% improved from baseline and maintained for at least 6 weeks. Worsened is indicated by subscale score at least 10% worse than baseline. Stable is indicated by neither improvement nor worsened. Achievement of improvement prior to worsening was classified as improvement.
Query!
Timepoint [6]
0
0
Baseline to treatment discontinuation every 6 weeks; The maximum time in follow up was 25 months
Query!
Secondary outcome [7]
0
0
Pharmacokinetic Measurements of Total Irinotecan
Query!
Assessment method [7]
0
0
Plasma concentration-time data for MM-398 will be analyzed using population pharmacokinetic methods.
Query!
Timepoint [7]
0
0
6 weeks after first study drug administration
Query!
Eligibility
Key inclusion criteria
* Histologically or cytologically confirmed adenocarcinoma of the exocrine pancreas
* Metastatic disease
* Documented disease progression after prior gemcitabine based therapy
* KPS >/= 70
* Adequate bone marrow function
* Adequate hepatic function
* Adequate renal function
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Active CNS metastasis
* Clinically significant GI disorders
* Severe arterial thromboembolic events less than 6 months before inclusion
* NYHA Class III or IV congestive heart failure, ventricular arrhythmias or uncontrolled blood pressure
* Active infection or uncontrolled fever
* Pregnant or breast feeding patients
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/11/2011
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/10/2015
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
417
Query!
Recruitment in Australia
Recruitment state(s)
NSW,SA,VIC,WA
Query!
Recruitment hospital [1]
0
0
- Westmead
Query!
Recruitment hospital [2]
0
0
- Kurralta Park
Query!
Recruitment hospital [3]
0
0
- Boxhill
Query!
Recruitment hospital [4]
0
0
- Heidelberg
Query!
Recruitment hospital [5]
0
0
- Melbourne
Query!
Recruitment hospital [6]
0
0
- Nedlands
Query!
Recruitment postcode(s) [1]
0
0
- Westmead
Query!
Recruitment postcode(s) [2]
0
0
- Kurralta Park
Query!
Recruitment postcode(s) [3]
0
0
- Boxhill
Query!
Recruitment postcode(s) [4]
0
0
- Heidelberg
Query!
Recruitment postcode(s) [5]
0
0
- Melbourne
Query!
Recruitment postcode(s) [6]
0
0
- Nedlands
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arizona
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Florida
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Georgia
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Missouri
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Nevada
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
New Mexico
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
New York
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Ohio
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Oklahoma
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
South Carolina
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Texas
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Virginia
Query!
Country [14]
0
0
Argentina
Query!
State/province [14]
0
0
Buenos Aires
Query!
Country [15]
0
0
Argentina
Query!
State/province [15]
0
0
Rosario
Query!
Country [16]
0
0
Argentina
Query!
State/province [16]
0
0
Santa Fe
Query!
Country [17]
0
0
Brazil
Query!
State/province [17]
0
0
Belo Horizonte
Query!
Country [18]
0
0
Brazil
Query!
State/province [18]
0
0
Ijui
Query!
Country [19]
0
0
Brazil
Query!
State/province [19]
0
0
Passo Fundo
Query!
Country [20]
0
0
Brazil
Query!
State/province [20]
0
0
Porto Alegre
Query!
Country [21]
0
0
Brazil
Query!
State/province [21]
0
0
Sao Paulo
Query!
Country [22]
0
0
Canada
Query!
State/province [22]
0
0
Quebec
Query!
Country [23]
0
0
Czech Republic
Query!
State/province [23]
0
0
Horovice
Query!
Country [24]
0
0
Czech Republic
Query!
State/province [24]
0
0
Olomouc
Query!
Country [25]
0
0
Czech Republic
Query!
State/province [25]
0
0
Prague
Query!
Country [26]
0
0
Czech Republic
Query!
State/province [26]
0
0
Pribram
Query!
Country [27]
0
0
France
Query!
State/province [27]
0
0
Bordeaux
Query!
Country [28]
0
0
France
Query!
State/province [28]
0
0
Lille
Query!
Country [29]
0
0
France
Query!
State/province [29]
0
0
Marseille
Query!
Country [30]
0
0
Germany
Query!
State/province [30]
0
0
Berlin
Query!
Country [31]
0
0
Germany
Query!
State/province [31]
0
0
Jens
Query!
Country [32]
0
0
Germany
Query!
State/province [32]
0
0
Munich
Query!
Country [33]
0
0
Germany
Query!
State/province [33]
0
0
Ulm
Query!
Country [34]
0
0
Hungary
Query!
State/province [34]
0
0
Budapest
Query!
Country [35]
0
0
Hungary
Query!
State/province [35]
0
0
Pecs
Query!
Country [36]
0
0
Hungary
Query!
State/province [36]
0
0
Szeged
Query!
Country [37]
0
0
Hungary
Query!
State/province [37]
0
0
Szolnok
Query!
Country [38]
0
0
Hungary
Query!
State/province [38]
0
0
Szombathely
Query!
Country [39]
0
0
Italy
Query!
State/province [39]
0
0
Castellana Grotte
Query!
Country [40]
0
0
Italy
Query!
State/province [40]
0
0
Genova
Query!
Country [41]
0
0
Italy
Query!
State/province [41]
0
0
Legnano
Query!
Country [42]
0
0
Italy
Query!
State/province [42]
0
0
Naples
Query!
Country [43]
0
0
Italy
Query!
State/province [43]
0
0
Roma
Query!
Country [44]
0
0
Korea, Republic of
Query!
State/province [44]
0
0
Hwasun-gun
Query!
Country [45]
0
0
Korea, Republic of
Query!
State/province [45]
0
0
Seoul
Query!
Country [46]
0
0
South Africa
Query!
State/province [46]
0
0
Port Elizabeth
Query!
Country [47]
0
0
South Africa
Query!
State/province [47]
0
0
Pretoria
Query!
Country [48]
0
0
South Africa
Query!
State/province [48]
0
0
Western Cape
Query!
Country [49]
0
0
Spain
Query!
State/province [49]
0
0
Alicante
Query!
Country [50]
0
0
Spain
Query!
State/province [50]
0
0
Barcelona
Query!
Country [51]
0
0
Spain
Query!
State/province [51]
0
0
Madrid
Query!
Country [52]
0
0
Spain
Query!
State/province [52]
0
0
Santander
Query!
Country [53]
0
0
Spain
Query!
State/province [53]
0
0
Valencia
Query!
Country [54]
0
0
Taiwan
Query!
State/province [54]
0
0
Chiayi
Query!
Country [55]
0
0
Taiwan
Query!
State/province [55]
0
0
Kaohsiung
Query!
Country [56]
0
0
Taiwan
Query!
State/province [56]
0
0
Taiching
Query!
Country [57]
0
0
Taiwan
Query!
State/province [57]
0
0
Tainan
Query!
Country [58]
0
0
Taiwan
Query!
State/province [58]
0
0
Taipei
Query!
Country [59]
0
0
Taiwan
Query!
State/province [59]
0
0
Taoyuan
Query!
Country [60]
0
0
United Kingdom
Query!
State/province [60]
0
0
Liverpool
Query!
Country [61]
0
0
United Kingdom
Query!
State/province [61]
0
0
London
Query!
Country [62]
0
0
United Kingdom
Query!
State/province [62]
0
0
Manchester
Query!
Country [63]
0
0
United Kingdom
Query!
State/province [63]
0
0
Sutton
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Merrimack Pharmaceuticals
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The study is an open label, randomized phase 3 study of MM-398 with or without 5-Fluorouracil (5-FU) and Leucovorin (also known as folinic acid), versus 5-FU and leucovorin in metastatic pancreatic cancer patients who have progressed on prior gemcitabine based therapy.
Query!
Trial website
https://clinicaltrials.gov/study/NCT01494506
Query!
Trial related presentations / publications
Chen LT, Macarulla T, Blanc JF, Mirakhur B, de Jong FA, Belanger B, Bekaii-Saab T, Siveke JT. Early dose reduction/delay and the efficacy of liposomal irinotecan with fluorouracil and leucovorin in metastatic pancreatic ductal adenocarcinoma (mPDAC): A post hoc analysis of NAPOLI-1. Pancreatology. 2021 Jan;21(1):192-199. doi: 10.1016/j.pan.2020.10.029. Epub 2020 Oct 10. Macarulla Mercade T, Chen LT, Li CP, Siveke JT, Cunningham D, Bodoky G, Blanc JF, Lee KH, Dean A, Belanger B, Wang-Gillam A. Liposomal Irinotecan + 5-FU/LV in Metastatic Pancreatic Cancer: Subgroup Analyses of Patient, Tumor, and Previous Treatment Characteristics in the Pivotal NAPOLI-1 Trial. Pancreas. 2020 Jan;49(1):62-75. doi: 10.1097/MPA.0000000000001455. Erratum In: Pancreas. 2020 Mar;49(3):e27. doi: 10.1097/MPA.0000000000001517. Bang YJ, Li CP, Lee KH, Chiu CF, Park JO, Shan YS, Kim JS, Chen JS, Shim HJ, Rau KM, Choi HJ, Oh DY, Belanger B, Chen LT. Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: Subgroup analysis of the NAPOLI-1 study. Cancer Sci. 2020 Feb;111(2):513-527. doi: 10.1111/cas.14264. Epub 2019 Dec 20. Macarulla T, Blanc JF, Wang-Gillam A, Chen LT, Siveke JT, Mirakhur B, Chen J, de Jong FA. Liposomal irinotecan and 5-fluorouracil/leucovorin in older patients with metastatic pancreatic cancer - A subgroup analysis of the pivotal NAPOLI-1 trial. J Geriatr Oncol. 2019 May;10(3):427-435. doi: 10.1016/j.jgo.2019.02.011. Epub 2019 Mar 4. Wang-Gillam A, Hubner RA, Siveke JT, Von Hoff DD, Belanger B, de Jong FA, Mirakhur B, Chen LT. NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors. Eur J Cancer. 2019 Feb;108:78-87. doi: 10.1016/j.ejca.2018.12.007. Epub 2019 Jan 14. Chen LT, Siveke JT, Wang-Gillam A, Li CP, Bodoky G, Dean AP, Shan YS, Jameson GS, Macarulla T, Lee KH, Cunningham D, Blanc JF, Chiu CF, Schwartsmann G, Braiteh FS, Mamlouk K, Belanger B, de Jong FA, Hubner RA. Survival with nal-IRI (liposomal irinotecan) plus 5-fluorouracil and leucovorin versus 5-fluorouracil and leucovorin in per-protocol and non-per-protocol populations of NAPOLI-1: Expanded analysis of a global phase 3 trial. Eur J Cancer. 2018 Dec;105:71-78. doi: 10.1016/j.ejca.2018.09.010. Epub 2018 Nov 8. Wang-Gillam A, Li CP, Bodoky G, Dean A, Shan YS, Jameson G, Macarulla T, Lee KH, Cunningham D, Blanc JF, Hubner RA, Chiu CF, Schwartsmann G, Siveke JT, Braiteh F, Moyo V, Belanger B, Dhindsa N, Bayever E, Von Hoff DD, Chen LT; NAPOLI-1 Study Group. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet. 2016 Feb 6;387(10018):545-557. doi: 10.1016/S0140-6736(15)00986-1. Epub 2015 Nov 29. Erratum In: Lancet. 2016 Feb 6;387(10018):536. doi: 10.1016/S0140-6736(15)01306-9.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Eliel Bayever, MD
Query!
Address
0
0
Merrimack Pharmaceuticals
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results are available at
https://clinicaltrials.gov/study/NCT01494506
Download to PDF